EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Performance of BIOFIRE FILMARRAY pneumonia panel in suspected pneumonia: insights from a real-world study

Mona Mustafa Hellou iD, Abinash Virk, Angel P Strasburg, William S Harmsen, Paschalis Vergidis iD, Kirstin Kooda, Kami D Kies, Alexander D Donadio, Jay Mandrekar, Audrey N Schuetz iD, Robin Patel iD

Microbiology Spectrum · 2025

DOI: 10.1128/spectrum.00571-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, 2025. Verfasst von Mona Mustafa Hellou und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Molecular Diagnostic Techniques, Pneumonia, Bacterial, Pneumonia, Bacteria. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pneumonia may be caused by a diverse group of microorganisms; however, a microbiologic diagnosis is not universally made. Molecular tests such as the BIOFIRE FILMARRAY Pneumonia Panel (BF-PP) offer the possibility of rapid identification of potential pneumonia pathogens. This retrospective analysis was conducted as a sub-study of a recently published randomized controlled trial. Specimens from patients with suspected pneumonia were tested by the BF-PP, with results compared to cultures. The overall BF-PP positivity rate was 44.8% (252/563), and was higher [64.6% (164/254)] in specimens from patients ultimately diagnosed with pneumonia. Discrepancies between the BF-PP and cultures were most common for Streptococcus pneumoniae , Haemophilus influenzae , Moraxella catarrhalis, and Streptococcus agalactiae . Positive percent agreement (PPA) and negative percent agreement (NPA) between the BF-PP and culture were 91.4% (CI 86.3%–94.9%) and 83.6% (CI 79.5%–87.2%), respectively. For most bacteria, a correlation between high genomic abundance (genomic copies/mL) reported from the BF-PP and culture growth abundance was found. In specimens from patients ultimately diagnosed with pneumonia, clinical consistency—assessed based on whether BF-PP results aligned with associated culture results—was 79.9% and was highest for bronchoalveolar lavage fluid specimens. The BF-PP has reliable analytical performance and offers the potential advantage over conventional cultures of providing higher detection rates and more rapid results. Interestingly, despite the use of this advanced molecular diagnostic tool, one-third of pneumonia cases remained without a microbiologic etiology. IMPORTANCE This study evaluates the BIOFIRE FILMARRAY Pneumonia Panel by comparing its performance to conventional cultures in a real-world patient population (including patients ultimately diagnosed as not having pneumonia) using different types of specimens. Findings show a higher detection rate of microorganisms with the panel compared to cultures, suggesting that this test could aid in tailoring treatments for pneumonia. However, challenges remain and require further study, including distinguishing true pathogens from colonizing microorganisms and determinig why one-third of patients diagnosed with pneumonia still lacked a microbiologic etiology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Molecular Diagnostic TechniquesPneumonia, BacterialPneumoniaBacteriaHumansRetrospective StudiesMaleFemaleMiddle AgedAgedAdultStreptococcus pneumoniaeMoraxella catarrhalisAged, 80 and overSensitivity and Specificity

Stichwörter der Autor:innen

BIOFIREanalytical performanceconcordancenegative percent agreementpneumoniapositive percent agreement

Autor:innen und Institutionen

  • Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
  • Division of Public Health, Infectious Diseases, and Occupational Medicine, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Pharmacy, Mayo Clinic, Rochester, Minnesota, USA.

ORCID-Profile: Mona Mustafa Hellou, Paschalis Vergidis, Audrey N Schuetz, Robin Patel

Zitieren

APA

Mustafa Hellou, M., Virk, A., Strasburg, A. P., Harmsen, W. S., Vergidis, P., Kooda, K., Kies, K. D., Donadio, A. D., Mandrekar, J., Schuetz, A. N., & Patel, R. (2025). Performance of BIOFIRE FILMARRAY pneumonia panel in suspected pneumonia: insights from a real-world study. Microbiology Spectrum. https://doi.org/10.1128/spectrum.00571-25

Vancouver

Mustafa Hellou M, Virk A, Strasburg AP, Harmsen WS, Vergidis P, Kooda K, et al. Performance of BIOFIRE FILMARRAY pneumonia panel in suspected pneumonia: insights from a real-world study. Microbiology Spectrum. 2025. doi:10.1128/spectrum.00571-25

BibTeX
@article{MustafaHellou2025,
  author = {Mustafa Hellou, Mona and Virk, Abinash and Strasburg, Angel P and Harmsen, William S and Vergidis, Paschalis and Kooda, Kirstin and Kies, Kami D and Donadio, Alexander D and Mandrekar, Jay and Schuetz, Audrey N and Patel, Robin},
  title = {Performance of BIOFIRE FILMARRAY pneumonia panel in suspected pneumonia: insights from a real-world study},
  journal = {Microbiology Spectrum},
  year = {2025},
  doi = {10.1128/spectrum.00571-25}
}
Kostenlos starten →